Literature DB >> 25311426

Aloin delivery on buccal mucosa: ex vivo studies and design of a new locoregional dosing system.

Viviana De Caro1, Anna Lisa Scaturro, Giulia Di Prima, Giuseppe Avellone, Flavia Maria Sutera, Olga Di Fede, Giuseppina Campisi, Libero Italo Giannola.   

Abstract

CONTEXT: Chemoprevention of potential malignant disorders or cancerous lesions that affect oral mucosae requires extended duration of treatment. Locoregional delivery of natural products could represent a promising strategy for this purpose.
OBJECTIVE: To investigate the aptitude of aloin to permeate through, or accumulate in, the buccal mucosa and to develop a new prolonged oro-mucosal drug delivery system.
MATERIALS AND METHODS: Permeation/accumulation of aloin from Curacao Aloe (containing 50% barbaloin) was evaluated ex vivo, using porcine buccal mucosa as the most useful model to simulate human epithelium. Oro-mucosal matrix tablets were prepared by dispersing aloin (10% w/w) in Eudragit® RS 100 as, biocompatible, low permeable, pH-independent, and non-swelling polymer. The prepared tablets were evaluated for drug-polymer compatibility, weight variation, drug uniformity content, diameter, thickness, hardness, friability, swelling, mucoadhesive strength, and drug release.
RESULTS: Aloin has low tendency to cross buccal mucosa, permeation is marginal, and high drug amounts remain entrapped into the epithelium. Matrix tablets characteristics were in agreement with pharmacopoeial requirements. Drug release showed highly reproducible Higuchian profile. Delivery through matrix tablets promoted drug accumulation in the mucosal tissue. DISCUSSION AND
CONCLUSION: Following application of matrix tablets on porcine buccal mucosa, the amount of discharged drug recovered in the tissue should be sufficient to produce the desired effects, providing therapeutic drug levels directly at the site of action. Aloin-loaded tablets are valid candidates for prevention/treatment of potentially malignant disorders and oral cancer and could potentially lead to clinically relevant drug delivery system as coadjuvant of conventional chemotherapy/radiation therapy.

Entities:  

Keywords:  Aloin matrix tablets; barbaloin; buccal mucosa; buccal tablets; locoregional drug delivery; oro-mucosal delivery

Mesh:

Substances:

Year:  2015        PMID: 25311426     DOI: 10.3109/03639045.2014.971030

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  5 in total

1.  Transbuccal delivery of betahistine dihydrochloride from mucoadhesive tablets with a unidirectional drug flow: in vitro, ex vivo and in vivo evaluation.

Authors:  Mohamed A El-Nabarawi; Adel A Ali; Heba M Aboud; Amira H Hassan; Amany H Godah
Journal:  Drug Des Devel Ther       Date:  2016-12-14       Impact factor: 4.162

2.  Bioadhesive Matrix Tablets Loaded with Lipophilic Nanoparticles as Vehicles for Drugs for Periodontitis Treatment: Development and Characterization.

Authors:  Denise Murgia; Giuseppe Angellotti; Fabio D'Agostino; Viviana De Caro
Journal:  Polymers (Basel)       Date:  2019-11-02       Impact factor: 4.329

3.  Spray-Dried Cytisine-Loaded Matrices: Development of Transbuccal Sustained-Release Tablets as a Promising Tool in Smoking Cessation Therapy.

Authors:  Giuseppe Angellotti; Giulia Di Prima; Amalia Giulia Scarpaci; Fabio D'Agostino; Giuseppina Campisi; Viviana De Caro
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525

4.  Chlorhexidine Mucoadhesive Buccal Tablets: The Impact of Formulation Design on Drug Delivery and Release Kinetics Using Conventional and Novel Dissolution Methods.

Authors:  Enas Al-Ani; David Hill; Khalid Doudin
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-23

5.  Development and Characterization of an Amorphous Solid Dispersion of Furosemide in the Form of a Sublingual Bioadhesive Film to Enhance Bioavailability.

Authors:  Viviana De Caro; Alessia Ajovalasit; Flavia Maria Sutera; Denise Murgia; Maria Antonietta Sabatino; Clelia Dispenza
Journal:  Pharmaceutics       Date:  2017-06-24       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.